Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARS Pharmaceuticals, Inc.SBTX · Entity 883 | President and CSO | May 02, 2022 | May 04, 2022 |
| Odyssey Therapeutics, Inc.ODTX · Entity 4850 | Director | May 07, 2026 | May 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARS Pharmaceuticals, Inc.
Report date May 02, 2022 · Filed May 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,639 |
Reported balance
After 2022-05-02 transaction · row 1
1 source rowRow 1 · 2022-05-02 · Grant · Acquired 45,233 · Balance 61,639 F1: The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.15 · Expires 2032-05-01 | Direct | 90,467 |
Reported balance
After 2022-05-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-02 · Grant · Acquired 90,467 · Balance 90,467 F2: The shares subject to the option will vest on May 2, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock.
F2: The shares subject to the option will vest on May 2, 2023.
Odyssey Therapeutics, Inc.
Report date May 07, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-05-06 | Direct | 27,393 |
Reported balance
After 2026-05-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-07 · Grant · Acquired 27,393 · Balance 27,393 F1: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2026 Filed May 12, 2026 00:30 UTC | Odyssey Therapeutics, Inc. ODTX · Entity 4850 | GrantStock Option (Right to Buy) · Derivative | 27,393 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001193125-26-217590 · ownership.xml · derivative · entry 1 Odegard Valerie · CIK 0001832432 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,393 Underlying: Common Stock · 27,393 shares Expires 2036-05-06 F1 · derivative.exercise_date: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:12 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | GrantStock Option (right to buy) · Derivative | 90,467 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001209191-22-027158 · doc4.xml · derivative · entry 2 Odegard Valerie · CIK 0001832432 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,467 Underlying: Common Stock · 90,467 shares Expires 2032-05-01 F2 · derivative.exercise_date: The shares subject to the option will vest on May 2, 2023. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:12 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | GrantCommon Stock | 45,233 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-027158 · doc4.xml · nonDerivative · entry 1 Odegard Valerie · CIK 0001832432 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,639 F1 · shares: The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:16 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | GrantStock Option (right to buy) · Derivative | 49,875 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001209191-22-006434 · doc4.xml · derivative · entry 3 Odegard Valerie · CIK 0001832432 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,875 Underlying: Common Stock · 49,875 shares Expires 2032-01-31 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2023, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:16 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | GrantStock Option (right to buy) · Derivative | 98,438 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001209191-22-006434 · doc4.xml · derivative · entry 2 Odegard Valerie · CIK 0001832432 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,438 Underlying: Common Stock · 98,438 shares Expires 2032-01-31 F2 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 48 months following February 1, 2022. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:16 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | GrantCommon Stock | 16,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006434 · doc4.xml · nonDerivative · entry 1 Odegard Valerie · CIK 0001832432 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,406 F1 · shares: The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 03, 2020 Filed Dec 8, 2020 01:01 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | GrantStock Option (right to buy) · Derivative | 364,904 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001209191-20-062054 · doc4.xml · derivative · entry 1 Odegard Valerie · CIK 0001832432 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,904 Underlying: Common Stock · 364,904 shares Expires 2030-12-02 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 48 months following December 3, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.